Clinical Trial Update: A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update indicates Novartis is evaluating Votoplam for Huntington's disease. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• Votoplam

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Huntington Disease | Phase 3 | Status: RECRUITING